SCHEMBL5841935

SCHEMBL5841935

Cc1cc(C)nc(N(C)c2ccc(NC(=O)C3CC(=O)N(CCc4ccccn4)C3)cc2)n1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.47
LMNA P02545 3/20 0.47
HTT P42858 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
SMN1; SMN2 Q16637 6/20 0.44
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
MAPT P10636 3/20 0.42
NPC1 O15118 1/20 0.42
GLA P06280 1/20 0.42
RAB9A P51151 1/20 0.42
KDM4E B2RXH2 1/20 0.41
HPGD P15428 1/20 0.41
MCL1 Q07820 1/20 0.41
HIF1A Q16665 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
SCN5A Q14524 1/20 0.41
SCN9A Q15858 1/20 0.41
GFER P55789 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5841677 0.90 ALDH1A1 (0.49) ALDH1A1LMNAHTTL3MBTL1SMN1; SMN2
SCHEMBL5842690 0.88 SMN1; SMN2 (0.57) ALDH1A1LMNAHTTL3MBTL1SMN1; SMN2
SCHEMBL5842238 0.86 ALDH1A1 (0.51) ALDH1A1LMNAHTTL3MBTL1SMN1; SMN2
SCHEMBL6617086 0.86 KMT2A (0.36) ALDH1A1LMNASMN1; SMN2KMT2AMEN1
SCHEMBL5841926 0.86 ALDH1A1 (0.48) ALDH1A1LMNAHTTL3MBTL1SMN1; SMN2
SCHEMBL5841681 0.84 ALDH1A1 (0.47) ALDH1A1LMNAHTTL3MBTL1SMN1; SMN2
SCHEMBL5841684 0.84 ALDH1A1 (0.44) ALDH1A1LMNAHTTL3MBTL1SMN1; SMN2
SCHEMBL5842943 0.84 RXFP3 (0.51) ALDH1A1LMNAHTTL3MBTL1SMN1; SMN2
SCHEMBL5841229 0.83 ALDH1A1 (0.68) ALDH1A1LMNAHTTL3MBTL1SMN1; SMN2
SCHEMBL5841923 0.81 ALDH1A1 (0.51) ALDH1A1LMNAHTTL3MBTL1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7067549-B2 Pyrrolidone carboxamides ACTELION PHARMACEUTICALS AG (CH) 2006-06-27 US disclosed
US-20050192292-A1 Pyrrolidone carboxamides ACTELION PHARMACEUTICALS AG (CH) 2005-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050192292-A1 Pyrrolidone carboxamides NPY1R, NPY5R, NPY2R ALDH1A1 3034/4885LMNA 3430/4885HTT 607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.